Cargando…
Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection
Respiratory syncytial virus (RSV) accounts for about 20% of all respiratory infections in children below the age of 5 y. It is associated with up to 63% of all acute respiratory infections and up to 81% of all viral lower respiratory tract infections causing hospitalization in infants and young chil...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5612471/ https://www.ncbi.nlm.nih.gov/pubmed/28605249 http://dx.doi.org/10.1080/21645515.2017.1337614 |